Apyx Medical Co. (NASDAQ:APYX) to Post FY2021 Earnings of ($0.43) Per Share, Colliers Securities Forecasts

Apyx Medical Co. (NASDAQ:APYX) – Research analysts at Colliers Securities boosted their FY2021 earnings per share estimates for Apyx Medical in a research report issued on Tuesday, January 11th. Colliers Securities analyst K. Bauser now anticipates that the company will earn ($0.43) per share for the year, up from their prior estimate of ($0.50). Colliers Securities also issued estimates for Apyx Medical’s Q4 2021 earnings at ($0.13) EPS and FY2022 earnings at ($0.38) EPS.

Apyx Medical (NASDAQ:APYX) last posted its quarterly earnings results on Thursday, November 11th. The company reported ($0.12) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.03. The firm had revenue of $11.83 million during the quarter, compared to analysts’ expectations of $10.83 million. Apyx Medical had a negative return on equity of 24.87% and a negative net margin of 34.05%. During the same quarter in the previous year, the business earned ($0.13) earnings per share.

APYX has been the subject of several other research reports. Piper Sandler increased their target price on Apyx Medical from $14.00 to $20.00 and gave the stock an “overweight” rating in a research report on Thursday, November 11th. JMP Securities reissued a “buy” rating and set a $17.00 price objective on shares of Apyx Medical in a research note on Friday, November 12th. Finally, Zacks Investment Research raised shares of Apyx Medical from a “hold” rating to a “buy” rating and set a $14.00 target price on the stock in a research note on Thursday.

APYX opened at $11.63 on Thursday. Apyx Medical has a 12-month low of $8.65 and a 12-month high of $17.50. The company’s 50 day moving average is $13.71 and its 200 day moving average is $12.08. The company has a market cap of $399.42 million, a price-to-earnings ratio of -27.69 and a beta of 0.87.

Several hedge funds have recently modified their holdings of APYX. Captrust Financial Advisors raised its holdings in Apyx Medical by 69.0% in the 3rd quarter. Captrust Financial Advisors now owns 2,450 shares of the company’s stock worth $34,000 after purchasing an additional 1,000 shares during the period. Lazard Asset Management LLC purchased a new stake in shares of Apyx Medical in the second quarter valued at approximately $37,000. Citigroup Inc. grew its position in shares of Apyx Medical by 125.8% in the third quarter. Citigroup Inc. now owns 3,489 shares of the company’s stock valued at $48,000 after purchasing an additional 1,944 shares in the last quarter. Advisory Services Network LLC purchased a new stake in shares of Apyx Medical in the second quarter valued at approximately $52,000. Finally, BNP Paribas Arbitrage SA grew its position in Apyx Medical by 289.8% in the third quarter. BNP Paribas Arbitrage SA now owns 5,445 shares of the company’s stock worth $75,000 after acquiring an additional 4,048 shares during the period. 59.97% of the stock is owned by institutional investors and hedge funds.

Apyx Medical Company Profile

Apyx Medical Corp. operates as an energy-based medical technology company. The firm engages in developing, manufacturing, and marketing a range of electrosurgical products and technologies, as well as related medical products used the offices of doctors, surgery centers, and hospitals worldwide. It operates through the following segments: Advanced Energy and Original Equipment Manufacture (OME).

See Also: What is Cost of Goods Sold (COGS)?

Earnings History and Estimates for Apyx Medical (NASDAQ:APYX)

Receive News & Ratings for Apyx Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apyx Medical and related companies with MarketBeat.com's FREE daily email newsletter.